Evaluation of anticonvulsant and analgesic effects of benzyl- and benzhydryl ureides

European Journal of Pharmacology

Volumn 559, Issue 2-3, 2007, Pages 138-149

  Librowski, Tadeusz ^a   Kubacka, Monika ^a   Meusel, Manuela ^b   Scolari, Silvia ^b   Müller, Christa E ^b   Gütschow, Michael ^b  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Adenosine receptors; Analgesic effect; Anticonvulsant activity; Benzodiazepine binding site; GABA; Ureides

Indexed keywords

1 BENZYL 3 BUTYRYLUREA; 2 CHLORO 6 N CYCLOPENTYLADENOSINE; 2 CHLOROADENOSINE; 4 AMINOBUTYRIC ACID A RECEPTOR; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A1 RECEPTOR; BENZHYDRYL DERIVATIVE; BENZODIAZEPINE; CARBANILAMIDE; DIAZEPAM; ETHOSUXIMIDE; IMIDAZOLE DERIVATIVE; METHYLCELLULOSE; PENTETRAZOLE; PHENYLISOPROPYLADENOSINE; PHENYTOIN; PICROTOXIN; UNCLASSIFIED DRUG; XANTHINE DERIVATIVE;

ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING SITE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ELECTRIC SHOCK; HOT PLATE TEST; LOCOMOTION; MALE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SEIZURE; STRUCTURE ACTIVITY RELATION;

ANALGESICS; ANIMALS; ANTICONVULSANTS; BENZHYDRYL COMPOUNDS; BENZYL COMPOUNDS; BINDING, COMPETITIVE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROSHOCK; HEAT; MALE; MICE; MOLECULAR STRUCTURE; MOTOR ACTIVITY; PAIN MEASUREMENT; PAIN THRESHOLD; PENTYLENETETRAZOLE; PICROTOXIN; RECEPTORS, GABA-A; RECEPTORS, PURINERGIC P1; SEIZURES; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

EID: 33847108902     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.12.002     Document Type: Article

References (70)

1. 2B adenosine receptor antagonists. J. Pharmacol. Exp. Ther. 308 (2004) 358-366
2. 2A receptor agonists on pentylenetetrazole-induced convulsions in the rat. Eur. J. Pharmacol. 294 (1995) 383-389
3. Arbuzov B.A., Fedotova N.R., Zobova N.N., Nazyrova A.Z., Anan'ev E.V., and Gorbunov S.M. Synthesis, antiinflammatory and analgesic activities of N-acylureas. Khim.-Farm. Zh. 23 (1989) 682-683
4. Baraldi P.G., Guarneri M., Manfredini S., Simoni D., and Zanirato V. Synthesis and evaluation of the antifungal activity of a new series of N-acylureas. Farmaco 44 (1989) 391-398
5. Baulac M. Rational conversion from antiepileptic polytherapy to monotherapy. Epileptic Disord. 5 (2003) 125-132
6. Beasley Y.M., Petrow V., and Stephenson O. Some 1-Alkyl-3-aroyl ureas. J. Pharm. Pharmacol. 13 (1961) 694-697
7. Beghi E., and Perucca E. The management of epilepsy in the 1990s. Acquisitions, uncertainties and priorities for future research. Drugs 49 (1995) 680-694
8. Blackburn-Munro G., and Jensen B.S. The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain. Eur. J. Pharmacol. 460 (2003) 109-116
9. Boissier J.R., Tardy J., and Diverres J.C. Une nouvelle méthode simple pour explorer l'action 'tranquillisante': le test de la cheminée. Med. Exp. 3 (1960) 81-84
10. Bryans J.S., and Wustrow D.J. 3-Substituted GABA analogs with central nervous system activity: a review. Med. Res. Rev. 19 (1999) 149-177
11. Bulicz J., Bertarelli D.C., Baumert D., Fülle F., Müller C.E., and Heber D. Synthesis and pharmacology of pyrido[2,3-d]pyrimidinediones bearing polar substituents as adenosine receptor antagonists. Bioorg. Med. Chem. 14 (2006) 2837-2849
12. Carraz G., and Emin N. Anticonvulsive action of di-n-propylacetic acid monoureide and of hydantoin derivatives of this acid. Thérapie 22 (1967) 641-652
13. Chiti W. New ureides with local anesthetic action. Farmaco Sci. 15 (1960) 29-43
14. Collins S.L., Moore R.A., McQuay H.J., and Wiffen P. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J. Pain Symp. Manage. 20 (2000) 449-458
15. De Sarro G., De Sarro A., Donato Di Paola E., and Bertorelli R. Effects of adenosine receptor agonists and antagonists on audiogenic seizure-sensible DBA/2 mice. Eur. J. Pharmacol. 371 (1999) 137-145
16. Drabczyńska A., Müller C.E., Schumacher B., Hinz S., Karolak-Wojciechowska J., Michalak B., Pekala E., and Kiec-Kononowicz K. Tricyclic oxazolo[2,3-f]purinediones: potency as adenosine receptor ligands and anticonvulsants. Bioorg. Med. Chem. 12 (2004) 4895-4908
17. During M.J., and Spencer D.D. Adenosine: a potential mediator of seizure arrest and postictal refractoriness. Ann. Neurol. 32 (1992) 618-624
18. Dunwiddie T.V. The physiological role of adenosine in the central nervous system. Int. Rev. Neurobiol. 27 (1985) 63-139
19. Eddy N.B., and Leimbach D. Synthetic analgesics. II. Dithienylbutenyl- and dithienylbutylamines. J. Pharmacol. Exp. Ther. 107 (1953) 385-393
20. Fredholm B.B., Chen J.F., Masino S.A., and Vaugeois J.M. Action of adenosine at its receptors in the CNS: insights from knockouts and drugs. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 385-412
21. Frommel E., and Radouco-Thomas C. Effects of phenobarbital, acylureas and diphenylhydantoin on coma during electric epileptic crisis in guinea pig. Helv. Physiol. Acta 11 (1953) 270-273
22. A receptors. Sci. Pharm. 64 (1996) 383-390
23. Giardina W.J., Decker M.W., Porsolt R.D., Roux S., Collins S.D., Kim D.J., and Bannon A.W. An evaluation of the GABA uptake blocker tiagabine on animal models of neuropathic and nociceptive pain. Drug Dev. Res. 44 (1998) 106-113
24. Goldstein L., and Pfeiffer C.C. Quantitative EEG analysis of single-dose effect relationships in normal volunteers of Pacinox® (capuride), a new antianxiety drug. Biol. Psychiatry 3 (1971) 165-172
25. Graber H., Árr M., Csiba A., Ludwig E., and Magyar T. Azlocillin and mezlocillin: new penicillins and their value. Orv. Hetil. 122 (1981) 749-756
26. 2B-selective adenosine receptor antagonists. J. Med. Chem. 45 (2002) 1500-1510
27. Hemmateenejad B., Miri R., Tabarzad M., Jafarpour M., and Zand F. Molecular modeling and QSAR analysis of the anticonvulsant activity of some N-phenyl-N′-(4-pyridinyl)-urea derivatives. J. Mol. Struct., Theochem 684 (2004) 43-49
28. A) receptors: mechanism and site of action. J. Pharmacol. Exp. Ther. 298 (2001) 986-995
29. Hunter J.C., Gogas K.R., Hedley L.R., Jacobson L.O., Kassotakis L., Thompson J., and Fontana D.J. The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain. Eur. J. Pharmacol. 324 (1997) 153-160
30. Jastrze{ogonek}bska-Wie{ogonek}sek M., Librowski T., Czarnecki R., Marona H., and Nowak G. Central activity of new xanthone derivatives with chiral center in some pharmacological tests in mice. Pol. J. Pharmacol. 55 (2003) 461-465
31. Jaworska-Feil L., Kajta M., Budziszewska B., Leskiewicz M., and Lason W. Protective effects of TRH and its stable analogue, RGH-2202, on kainate-induced seizures and neurotoxicity in rodents. Epilepsy Res. 43 (2001) 67-73
32. 1 receptor. Proc. Natl. Acad. Sci. 98 (2001) 9407-9412
33. Khalil M., and Weaver D.F. A pattern recognition study of acyclic ureide anticonvulsants. J. Pharm. Pharmacol. 42 (1990) 349-351
34. Kieć-Kononowicz K., Müller C.E., Pekala E., Karolak-Wojciechowska J., Handzlik J., and Łażewska D. Imidazo[2,1-b]thiazoles, imidazo[2,1-b]imidazoles and pyrrolo[1,2-c]imidazoles. Synthesis, structures and evaluation of benzodiazepine receptor binding. J. Heterocycl. Chem. 39 (2002) 243-253
35. Kieć-Kononowicz K., Karolak-Wojciechowska J., Michalak B., Pe{ogonek}kala E., Schumacher B., and Müller C.E. Imidazo[2,1-b]thiazepines. Synthesis, structures and evaluation of benzodiazepine receptor binding. Eur. J. Med. Chem. 39 (2004) 205-218
36. 1 adenosine receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 340 (1989) 679-683
37. Kulev L.P., and Dobychina N.S. N,N′-Benzylacyl derivatives of urea. Zh. Vses. Khim. Obshch. Mendeleeva 8 (1963) 701-702
38. Laughlin T.M., Tram K.V., Wilcox G.L., and Birnbaum A.K. Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception. J. Pharmacol. Exp. Ther. 302 (2002) 1168-1175
39. Löscher W., and Schmidt D. Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation?. Epilepsy Res. 17 (1994) 95-134
40. Marder M., Estiu G., Blanch L.B., Viola H., Wasowski C., Medina J.H., and Paladini A.C. Molecular modeling and QSAR analysis of the interaction of flavone derivatives with the benzodiazepine binding site of the GABA(A) receptor complex. Bioorg. Med. Chem. 9 (2001) 323-335
41. Mendyk A., Sałat K., Librowski T., Czarnecki R., and Malawska B. Influence of new γ-aminobutyric acid amide, derivatives and its phthalimide precursors on the central nervous system activity in mice. Pol. J. Pharmacol. 53 (2001) 689-693
42. Meusel M., and Gütschow M. Recent developments in hydantoin chemistry. A review. Org. Prep. Proced. Int. 36 (2004) 391-443
43. Mrongovius R.I. Structure-activity correlations for central depressant acylureas and alkylureas. Eur. J. Med. Chem. Chem. Ther. 10 (1975) 474-479
44. Mrongovius R.I., Gaff G.A., and Rand M.J. Comparison of the bromureide sedative-hypnotic drugs, bromvaletone (bromisoval) and carbromal, and their chloro analogues in mice. Clin. Exp. Pharmacol. Physiol. 3 (1976) 443-447
45. Mui W.C., Zbuzek V.K., and Wu W.H. GABA(A) antagonist and nicotin-induced antinociception. Life Sci. 61 (1997) PL 221-PL 225
46. 3H]MSX-2 (3-(3-hydroxypropyl)-7-methyl-8-(m-methoxystyryl)-1-propargylxanthine) to rat striatal membranes - a new, selective antagonist radioligand for A(2A) adenosine receptors. Eur. J. Pharm. Sci. 10 (2000) 259-265
47. Palluotto F., Carotti A., Casini G., Campagna F., Genchi G., Rizzo M., and De Sarro G.B. Structure-activity relationships of 2-aryl-2,5-dihydropyridazino[4,3-b]indol-3(3H)-ones at the benzodiazepine receptor. Bioorg. Med. Chem. 4 (1996) 2091-2104
48. Pavia M.R., Lobbestael S.J., Taylor C.P., Hershenson F.M., and Miskell D.L. N-phenyl-N′-pyridinylureas as anticonvulsant agents. J. Med. Chem. 33 (1990) 854-861
49. Polezhaeva A.I. A comparative investigation of the phenylacetyl urea and phenoxyacetyl urea anticonvulsant activity. Farmakol. Toksikol. 29 (1966) 278-281
50. C receptors. Mol. Pharmacol. 67 (2005) 470-479
51. Rogawski M.A. Molecular targets versus models for new antiepileptic drug discovery. Epilepsy Res. 68 (2006) 22-28
52. Rogawski M.A. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res. 69 (2006) 273-294
53. Rogawski M.A., and Löscher W. The neurobiology of antiepileptic drugs. Nat. Rev., Neurosci. 5 (2004) 553-564
54. Rogawski M.A., and Loscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat. Med. 10 (2004) 685-692
55. Sawynok J., and Liu X.J. Adenosine in the spinal cord and periphery: release and regulation of pain. Prog. Neurobiol. 69 (2003) 313-340
56. Sobol E., Bialer M., and Yagen B. Tetramethylcyclopropyl analogue of a leading antiepileptic drug, valproic acid. Synthesis and evaluation of anticonvulsant activity of its amide derivatives. J. Med. Chem. 47 (2004) 4316-4326
57. Spielman M.A., Geiszler A.O., and Close W.J. Anticonvulsant drugs. II. Some acylureas. J. Am. Chem. Soc. 70 (1948) 4189-4191
58. + channels as targets for anticonvulsant, analgesic and neuroprotective drugs. Curr. Pharm. Des. 2 (1996) 375-388
59. Teuber L., Watjens F., and Jensen L.H. Ligands for the benzodiazepine binding site - a survey. Curr. Pharm. Des. 5 (1999) 317-343
60. Todorovic S.M., Rastogi A.J., and Jevtovic-Todorovic V. Potent analgesic effects of anticonvulsants on peripheral thermal nociception in rats. Br. J. Pharmacol. 140 (2003) 255-260
61. Turski L., Cavalheiro E.A., Czuczwar S.J., Turski W.A., and Kleinrok Z. The seizures induced by pilocarpine: behavioral, electroencephalographic and neuropathological studies in rodents. Pol. J. Pharmacol. Pharm. 39 (1987) 545-555
62. Verli H., Albuquerque M.G., Bicca de Alencastro R., and Barreiro E.J. Local intersection volume: a new 3D descriptor applied to develop a 3D-QSAR pharmacophore model for benzodiazepine receptor ligands. Eur. J. Med. Chem. 37 (2002) 219-229
63. Vogel H.G., and Vogel W.H. Drug Discovery and Evaluation, Pharmacological Assays (1997), Springer, Berlin 260-261
64. Weaver Jr. C.E., Marek P., Park-Chung M., Tam S.W., and Farb D.H. Neuroprotective activity of a new class of steroidal inhibitors of the N-methyl-D-aspartate receptor. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 10450-10454
65. Weiss H. Capuride for sleep in rehabilitation patients: a controlled trial. Arch. Phys. Med. Rehabil. 52 (1971) 68-72
66. Wiffen P., Collins S., McQuay H., Carroll D., Jadad A., and Moore A. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst. Rev. (2005) Issue 3, CD001133
67. Wong M.G., Defina J.A., and Andrews P.R. Conformational analysis of clinically active anticonvulsant drugs. J. Med. Chem. 29 (1986) 562-572
68. Yamashita H., Ohno K., Amada Y., Hattori H., Ozawa-Funatsu Y., Toya T., Inami H., Shishikura J., Sakamoto S., Okada M., and Yamaguchi T. Effects of 2-[N-(4-chlorophenyl)-N-methylamino]-4H-pyrido[3.2-e]-1,3-thiazin-4-one (YM928), an orally active alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, in models of generalized epileptic seizure in mice and rats. J. Pharmacol. Exp. Ther. 308 (2004) 127-133
69. 1 receptors underlies anticonvulsant effect of CGS 21680. Eur. J. Pharmacol. 255 (1994) 239-243
70. Zirvi K.A., and Fakouhi T. Synthesis and neuropharmacology of butyrylureas. Farmaco Sci. 37 (1982) 335-342